Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Positive Results for Anti-Obesity Drug Oxyntomodulin

By Drug Discovery Trends Editor | June 6, 2011

 Prolor Biotech, Inc. reported positive results from a comparative animal study of its anti-obesity drug candidate oxyntomodulin (OXY-RPEG).

The study measured the potential therapeutic effect of OXY-RPEG injected once or twice weekly as measured by weight loss and reduction in food intake compared with being injected twice daily.

It was conducted using an animal model specifically designed to test anti-obesity drugs. In the study, OXY-RPEG injected either once or twice over a period of seven days demonstrated significantly higher weight loss, reduction of food intake and duration of weight loss activity compared with being injected twice daily.
 
Oxyntomodulin is a naturally occurring peptide hormone released by the digestive system that acts as a natural satiety signal to reduce food intake and increase energy expenditure following food ingestion. Previous studies in humans showed that oxyntomodulin can reduce appetite and food intake, leading to significant weight loss without apparent side effects.

 However, as a result of oxyntomodulin’s very short half-life, it had to be administered via three daily injections in these human studies. Prolor developed its longer-acting OXY-RPEG version by combining a naturally occurring oxyntomodulin with the company’s proprietary Reversible PEGylation technology designed to increase the half-life of therapeutic peptides and small molecules.
 
OXY-RPEG demonstrated greater potency, with the total dose administered over seven days containing approximately 15% of the cumulative dose of oxyntomodulin injected during the same period.

Release Date: June 6, 2011
Source: Prolor Biotech, Inc 


Filed Under: Drug Discovery

 

Related Articles Read More >

Sanders, King target DTC pharma ads but the industry worries more about threats to its $2B R&D model
Zoliflodacin wins FDA nod for treatment of gonorrhea
FDA approved ENFLONSIA for the prevention of RSV in Infants
First clinical study results of Dupixent for atopic dermatitis in patients with darker skin tones 
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE